Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INFINITY PHARMACEUTICALS, INC.

(INFI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/21/2021 10/22/2021 10/25/2021 10/26/2021 10/27/2021 Date
2.65(c) 2.59(c) 2.53(c) 2.52(c) 2.46(c) Last
1 677 358 1 106 584 1 031 457 1 167 268 838 554 Volume
-0.38% -2.26% -2.32% -0.40% -2.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1,78 M - -
Net income 2021 -47,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,45x
Yield 2021 -
Sales 2022 1,61 M - -
Net income 2022 -57,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,04x
Yield 2022 -
Capitalization 218 M 218 M -
Capi. / Sales 2021 123x
Capi. / Sales 2022 136x
Nbr of Employees 23
Free-Float 97,8%
More Financials
Company
Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for people with cancer. It is also focusing on advancing, eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme... 
More about the company
Ratings of Infinity Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about INFINITY PHARMACEUTICALS, INC.
10/26Infinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call..
BU
10/18INFINITY PHARMACEUTICALS : HC Wainwright Starts Infinity Pharmaceuticals at Buy With $9 Pr..
MT
09/20INFINITY PHARMACEUTICALS, INC.(NASDA : INFI) added to S&P Global BMI Index
CI
09/14INFINITY PHARMACEUTICALS : to Participate in Oppenheimer's Fall Healthcare Life Sciences a..
AQ
09/13INFINITY PHARMACEUTICALS : to Participate in Oppenheimer's Fall Healthcare Life Sciences a..
BU
09/07INFINITY PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/07Infinity Pharmaceuticals, Inc. Elects Brian Schwartz as Member of the Board, Effective..
CI
09/07INFINITY PHARMACEUTICALS : Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and..
BU
09/07Infinity Pharmaceuticals, Inc. Appoints Robert Ilaria as Chief Medical Officer and Bria..
CI
09/02INFINITY PHARMACEUTICALS : to Participate in Wells Fargo and H.C. Wainwright Investor Conf..
BU
08/04INFINITY PHARMACEUTICALS : Reports Inducement Grants to Chief Scientific Officer under Nas..
AQ
08/03INFINITY PHARMACEUTICALS : Reports Inducement Grants to Chief Scientific Officer under Nas..
BU
08/02Top Midday Gainers
MT
08/02INFINITY PHARMACEUTICALS : Thinking about buying stock in Infinity Pharmaceuticals, Autolu..
PR
08/02ANALYST RECOMMENDATIONS : ConvaTec, DiscoverIE, LKQ, Unite Group, WidomTree...
More news
News in other languages on INFINITY PHARMACEUTICALS, INC.
2015Les valeurs à suivre sur les marchés américains.
More news
Analyst Recommendations on INFINITY PHARMACEUTICALS, INC.
More recommendations
Chart INFINITY PHARMACEUTICALS, INC.
Duration : Period :
Infinity Pharmaceuticals, Inc. Technical Analysis Chart | INFI | US45665G3039 | MarketScreener
Technical analysis trends INFINITY PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,46 $
Average target price 8,86 $
Spread / Average Target 260%
EPS Revisions
Managers and Directors
Adelene Q. Perkins Chairman & Chief Executive Officer
Lawrence E. Bloch President & Treasurer
Melissa Hackel Vice President-Finance
Robert Ilaria Chief Medical Officer
Anthony B. Evnin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INFINITY PHARMACEUTICALS, INC.16.04%218
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528